Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1997; 78(01): 622-626DOI: 10.1055/s-0038-1657600 Bleeding and thrombosis in myeloproliferative disorders Schattauer GmbH Stuttgart Therapeutic Dilemmas: Balancing the Risks of Bleeding, Thrombosis, and Leukemic Transformation in Myeloproliferative Disorders (MPD) Scott Murphy Thomas Jefferson University, American Red Cross Blood Services, Penn-Jersey Region, Philadelphia, PA, USA › Author Affiliations Recommend Article Abstract PDF Download Buy Article PDF (1010 kb) References References 1 Gilliland DG, Blanchard KL, Bunn HF. Clonality in acquired hematologic disorders. Annu Rev Med 1991; 42: 491-506 2 Berk PD, Goldberg JD, Donovant PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132-143 3 Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-664 4 Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, Maillard JN, Pariente EA, Leporrier M, Rueff B, Muller O, Benhanou JP. Primary myeloproliferative disorder and hepatic vein thrombosis. Ann Intern Med 1985; 103: 329-334 5 Berk PD, Wasserman LR, Fruchtman SM. Treatment of Polycythemia Vera: A Summary of Clinical Trials Conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI. eds. Polycythemia Vera and the Myeloproliferative Disorders. W.B. Saunders; Philadelphia, PA: 1995. pp 166-194 6 Mitus AJ, Barbui T, Shulman LN. Hemostatic complications in young patients with essential thrombocythemia. J Clin Oncol 1990; 88: 371-375 7 Millard FE, Hunter CS, Anderson M, Edelman MJ, Kosty MP, Luiken GA, Marino GG. Clinical manifestations of essential thro-mbocythemia in young adults. Am J Hematol 1990; 33: 27-31 8 Randi ML, Fabris F, Girolami A. Thrombocytosis in young people: Evaluation of 57 cases diagnosed before the age of 40. Blut 1990; 60: 233-237 9 Cortelazzo S, Viero P, Finazzi G, Emblio AD, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 08: 556-562 10 McIntyre KJ, Hoagland HC, Silverstein MN. et al. Essential thrombocythemia in young adults. Mayo Clin Proc 1991; 66: 149-154 11 Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. Ann Hematol 1991; 63: 101-106 12 Berlin NJ. Diagnosis and classification of the polycythemias. Semin Hematol 1976; 12: 339-351 13 Holme S, Murphy S. Platelet abnormalities in myeloproliferative disorders, in Davey FR (ed): Clinics in Laboratory Medicine: Myeloproliferative Disorders. 10 WB Saunders, Philadelphia, PA 1990; pp 873-888 14 Murphy S, Davis JL, Walsh PN, Gardner FH. Template bleeding time and clinical hemorrhage in myeloproliferative disease. Arch Intern Med 1978; 138: 1251-1253 15 Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658-2663 16 Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a PVSG report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34: 17-23 17 Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39 18 Najean Y, Dresch C, Rain JD. The very-long-term course of polycythemia: a complement to the previously published data of the Polycythemia Vera Study Group. Br J Haematol 1994; 86: 233-235 19 Murphy S, Iland H, Rosenthal D, Laszio J. Essential thrombocythemia: An interim report from the polycythemia vera study group. Semin Hematol 1986; 23: 177-182 20 Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR. Polycythemia vera: An update. II. Long-term management of polycythemia vera with hydroxyurea: A progress report. Semin Hematol 1986; 23: 167-171 21 Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, and Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New Engl J Med 1995; 332 (17) 1132-1136 22 Donehower RC. Hydroxyurea. in Chabner B. (ed). Pharmacological Principles of Cancer Treatment. W.B. Saunders; Philadelphia, PA: 1982. p 269 23 Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berges R, Boiron M. Essential thrombocythemia. Cancer 1986; 58: 2440-2447 24 Nand S, Messmore H, Fisher SG. Leukemic transformation in polycythemia vera: Analysis of risk factors. Am J Hematol 1987; 34: 32-36 25 Combi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67: 2926-2930 26 Lofvenberg E, Nordenson I, Wahlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer-Genet Cytogenet 1990; 49: 57-67 27 Scully RE, Mark EJ, McNeely WF, McNeely BU. Case records of the Massachusetts General Hospital, Case 31-1993. New Engl J Med 1993; 329: 417-423 28 Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J. Haematol 1994; 52: 134-139 29 Boivin P. Indications, procedure and results for the treatment of Polycythemia vera by bleeding, pipobroman and hydroxyurea. Nouv Rev Fr Hematol 1993; 35: 491-498 30 Murphy S. Polycythemia vera. In: Bone RC, Greenberger NJ, Kohler PO, Levin S, Lipschitz DA, Willerson JT. eds. Disease-a-Month, Mosby; Philadelphia, PA: 1992 31 Furgerson JL, Vukelja SJ, Baker WJ, O’Rourke TJ. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am J Hematol 1996; 51: 137-140 32 Nand S, Stock W, Godwin J, and Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol 1996; 52: 42-46 33 Murphy S, Rosenthal DS, Weinfield A, Briere J, Faquet GB, Knospe WH, Landaw SA, Laszio J, Pisciotta AV, Tartagia AP, Goldberg JD, Berk PD, Donovan PB, Wasserman LR. Essential thrombocythemia: Response during first year of therapy with melphalan and radioactive phosphorus: A polycythemia vera study group report. Cancer Treat Rep 1982; 66: 1495-1500 34 Lengfelder E, Griesshammer M, and Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leukemia and Lymphoma 1996; 22 (01) 135-142 35 Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin Hematol 1997; 34 (01) 40-50 36 Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman J. Increased incidence of second neoplasms in patients treated with interferon 2b for hairy cell leukemia: A clin-icopathologic assessment. Blood 1994; 83: 2931-2938 37 Ronnblom LE, Gunnar VA, Oberg KE. Autoimmunity after al-pha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178-183 38 Griesshammer M, Bangerter M, Seifried E. and the German ET-Study Group. Treatment and clinical course of essential thrombocythemia (ET): Preliminary results of a prospective multicenter trial. Brit J Haematol 1996; 93 (02) 234 39 Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients. Am J Med 1992; 92: 69-76 40 Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992; 79: 1931-1937 41 Silverstein MN, Chapman PetittRM, Mozeika SA, Fu J, and Caruso FS. Intense thrombocythemia associated with life-threatening symptoms and response to therapy. Blood 1992; 80: 214a 42 Silverstein M. Anagrelide in Myeloproliferative Diseases. In: Wasserman LR, Berk PD, Berlin NI. eds. Polycythemia Vera and the Myeloproliferative Disorders. W.B. Saunders; Philadelphia, PA: 1995. pp 329-336 43 Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of anti-aggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23: 172-176 44 Landolfi R and Patronos C. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. Leukemia and Lymphoma 1996; 22 (01) 83-86 45 Hirsh J, Salzman EW, Harker L, Fuster V, Dalen JE, Cairns JA, Collins R. Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects. Chest 1989; 95: 12S-18S 46 Murphy S. Polycythemia Vera and Essential Thrombocythemia. In: Cancer Medicine. 4th edition Holland JF, Base RC, Morton DL, Frei E, Kufe DW, Weichselbaum RR. eds. Williams & Wilkins; Philadelphia, PA: 1997. pp 2835-2846
